The 30-day estrogen clearance protocol is built on six interlocking pieces of biochemistry. This document walks through each one — what the literature says, what the protocol does about it, and why it matters specifically for endometriosis and adenomyosis.
For the full peer-reviewed bibliography, see research/. Citations here are anchors to the most important papers.
Endometriosis affects approximately 10% of women and people of reproductive age globally and is defined by ectopic endometrial tissue sustained by continuous estrogen exposure, with chronic pelvic pain, infertility, and systemic inflammation as core features.1 Ectopic endometriotic lesions express local aromatase, producing their own estrogen in a positive feedback loop, which is why suppressing systemic estrogen remains a cornerstone of pharmacologic management.2
Adenomyosis — where endometrial tissue invades the myometrium of the uterus — shares the estrogen-driven, inflammation-amplifying biology.
Implication: anything that reduces circulating estrogens, blocks their reactivation, or shifts them toward safer metabolites should — in principle — reduce the inflammatory and proliferative drive behind both conditions.
Circulating estrogens are cleared almost entirely through hepatic metabolism in two enzymatic phases:
CYP1A1, CYP1A2, CYP1B1, and CYP3A4 hydroxylate estrogen at the 2, 4, or 16 position:
The 2-OH : 4-OH ratio matters. Higher ratio = safer estrogen metabolism profile.
Four parallel pathways neutralize Phase 1 intermediates and make them water-soluble for excretion:
When Phase 1 is running fast but Phase 2 is bottlenecked, reactive intermediates accumulate. This drives oxidative stress and inflammation — the exact biology that worsens endometriosis.3
Altered expression of the sulfotransferase / sulfatase system has been documented specifically in endometriotic tissue (Piccinato et al. 2016)4 — suggesting the liver-estrogen axis isn’t only systemic; it’s locally disrupted at the lesion level. The protocol targets all four Phase 2 pathways with specific nutritional inputs.
Phase 2 methylation by COMT cannot happen without SAMe (S-adenosylmethionine). SAMe is produced by the methylation cycle, which runs on:
When the methylation cycle stalls, homocysteine accumulates (because it can’t be remethylated back to methionine). Elevated homocysteine is a direct biomarker that the cycle is bottlenecked.
The case-study evidence: the author’s homocysteine dropped from above-reference into the normal range during the case-study window. B12 simultaneously moved from low-normal to mid-normal. This is exactly the biomarker signature of restored methylation. See Case Study 001 biomarker results.
Implication: restoring methylation upstream is one of the highest-leverage interventions in this protocol. It enables COMT to do its job on 4-OH estrogens.
Endometriosis has documented associations with elevated tissue levels of dioxins, PCBs, bisphenols, and phthalates (Porpora et al. 2009;5 Smarr et al. 20166) — all lipid-soluble compounds that require the same Phase 1/Phase 2 machinery that clears estrogens.
When the liver is simultaneously metabolizing environmental estrogen mimics AND endogenous estrogens, capacity gets exceeded and both accumulate.
Implication: reducing inbound toxicant load (BPA-free plastics, clean personal care, organic where possible, filtered water) reduces Phase 1/Phase 2 traffic and frees capacity for endogenous estrogen clearance.
This is the mechanism most often underweighted in functional medicine and almost never addressed in mainstream endometriosis care. It is, in many patients, the structural reason a high-quality Phase 2 protocol produces only a partial response.
Cleared estrogens — already conjugated by the liver via glucuronidation or sulfation, packaged into bile, and excreted into the gut and reproductive tract — can be deconjugated by bacterial enzymes and reabsorbed into circulation. This is called enterohepatic recirculation in the gut and operates by the same enzymatic chemistry in the vagina.
The two key bacterial enzymes:
Both are produced widely across bacterial species in dysbiotic gut and vaginal communities — Escherichia coli, Clostridium spp., Bacteroides spp. in the gut, and Gardnerella spp., Prevotella spp., Atopobium vaginae (Fannyhessea vaginae), and Megasphaera in the vagina.
People with overgrowth of these bacteria — common in endometriosis populations per Salliss et al. 2021 — effectively recycle estrogens back into circulation that the liver had already worked to clear. This is the “estrobolome” mechanism, originally characterized for the gut by Baker et al. 2017 and now increasingly recognized as operating in the vagina as well.
The published research supports the mechanism in vitro and at the population level: bacteria with β-glucuronidase enzymes deconjugate cleared estrogens. CST-IV communities have higher β-glucuronidase activity than CST-I communities.
What is biologically plausible but NOT directly demonstrated in published cohort research:
In the case-study evidence for this protocol (see case-studies/001-core-restore-no-bc/):
The hypothesis that microbiome activity attenuated the protocol’s biological response is biologically plausible based on published mechanism but is not a measurement in this case study. It is a hypothesis to be tested by future research that directly characterizes both axes simultaneously in the same patients.
For the full discussion of what would need to be measured to test the integrative thesis rigorously, see case-studies/001-core-restore-no-bc/microbiome-estrogen-axis.md.
The estrobolome mechanism is well-characterized in the gut, primarily in oncology and pharmacology contexts (drug metabolism, ER-positive breast cancer). The vaginal microbiome is well-characterized as dysbiotic in endometriosis populations (Ata 2019, Salliss 2021).
What is NOT yet well-characterized in the published literature:
Each leg of the integrative thesis is supported separately by published research; the synthesis is currently theoretical (Salliss 2021 systematic review proposes it explicitly as a future research direction, but no empirical cohort has tested it).
This protocol incorporates microbiome-side support (Pillar 6) on the rational basis that the mechanism is published and the case-study author’s data is consistent with the framework — but the protocol’s design assumes a relationship between the two axes that has not been definitively shown in any cohort. A reader’s response to the protocol’s microbiome pillars may differ from the author’s case based on factors that the integrative research has not yet characterized.
This is one of the reasons Study 001 (Evvy + WHOOP citizen-science) and the dedicated microbiome-estrogen-axis.md framing exist in this repository. The integrative thesis is meant to motivate empirical research, not stand in for it.
The liver is the primary detoxification organ, but sweat is a real and clinically meaningful secondary excretion route for lipid-soluble xenobiotics:
The protocol’s sauna pillar provides a parallel clearance route for lipid-soluble xenoestrogens (BPA, phthalates, PCBs) that are elevated in endometriosis populations — particularly relevant alongside the liver-focused interventions.
HRV (heart rate variability) is a validated non-invasive proxy for both vagal tone and systemic inflammation (Thayer & Sternberg 2006).11 When HRV rises during an intervention, it’s a direct signal that inflammatory load on the autonomic nervous system is dropping.
Women with endometriosis have reduced baseline HRV compared to controls, independent of pain status (Kulshrestha et al. 2022)12 — confirming there’s a real, measurable autonomic deficit that an effective protocol should be able to move.
The case-study evidence: the author’s WHOOP-measured HRV moved meaningfully upward during the 14-day cycle, including during cycle-phase windows where HRV would naturally be suppressed. See Case Study 001 for the full data.
Implication: if you wear a WHOOP or Garmin during the protocol, the HRV response is your real-time signal of whether the inflammatory state is shifting. You don’t have to wait for bloodwork.
| Mechanism | Protocol pillar |
|---|---|
| Phase 1 → 2-OH direction | Cruciferous vegetables + DIM (practitioner) |
| Phase 2 methylation | Methylation nutrients (B12, B6, folate, magnesium, choline) |
| Phase 2 sulfation | Sulfur foods + NAC (practitioner) |
| Phase 2 glutathione | NAC + glycine + Vitamin C + selenium + sleep |
| Reduced toxicant influx | Clean personal care, glass containers, filtered water, organic when possible |
| Enterohepatic recirculation block | Fiber 30+ g/day, calcium-D-glucarate (practitioner), fermented foods |
| Sweat clearance | Infrared sauna 3–4x/week |
| Anti-inflammatory baseline | Omega-3, curcumin, elimination diet, anti-inflammatory whole foods |
| Stress / cortisol management | Sleep 8h, magnesium evening, breath protocol, restorative movement |
| Objective tracking | WHOOP/Garmin HRV + symptom log + pre/post bloodwork |
Zondervan KT, Becker CM, Missmer SA. “Endometriosis.” N Engl J Med. 2020;382(13):1244-1256. PMID: 32212520 ↩
Bulun SE. “Endometriosis.” N Engl J Med. 2009;360(3):268-279. PMID: 19144942 ↩
Cavalieri EL, Rogan EG. “Depurinating estrogen-DNA adducts, generators of cancer initiation: their minimization leads to cancer prevention.” Clin Transl Med. 2016;5(1):12. PMID: 27060235 ↩ ↩2
Piccinato CA, Neme RM, Torres N, et al. “Effects of steroid hormone on estrogen sulfotransferase and on steroid sulfatase expression in endometriosis tissue and stromal cells.” J Steroid Biochem Mol Biol. 2016;158:117-126. PMID: 26773670 ↩
Porpora MG, Medda E, Abballe A, et al. “Endometriosis and organochlorinated environmental pollutants.” Environ Health Perspect. 2009;117(7):1070-1075. PMID: 19654914 ↩
Smarr MM, Kannan K, Buck Louis GM. “Endocrine disrupting chemicals and endometriosis.” Fertil Steril. 2016;106(4):959-966. PMID: 27423382 ↩
Genuis SJ, Birkholz D, Rodushkin I, Beesoon S. “Blood, Urine, and Sweat (BUS) Study.” Arch Environ Contam Toxicol. 2011;61(2):344-357. PMID: 21057782 ↩
Sears ME, Kerr KJ, Bray RI. “Arsenic, Cadmium, Lead, and Mercury in Sweat: A Systematic Review.” J Environ Public Health. 2012;2012:184745. PMID: 22505948 ↩
Laukkanen T et al. “Association Between Sauna Bathing and Fatal Cardiovascular and All-Cause Mortality Events.” JAMA Intern Med. 2015;175(4):542-548. PMID: 25705824 ↩
Akin MD et al. “Continuous low-level topical heat in the treatment of dysmenorrhea.” Obstet Gynecol. 2001;97(3):343-349. PMID: 11239634 ↩
Thayer JF, Sternberg E. “Beyond heart rate variability: vagal regulation of allostatic systems.” Ann N Y Acad Sci. 2006;1088:361-372. PMID: 17192580 ↩
Kulshrestha R, Pandey A, Jain A, et al. “Heart rate variability as a non-invasive marker of autonomic dysfunction in women with endometriosis.” Indian J Physiol Pharmacol. 2022;66(4):263-270. ↩